Holen Sie sich die Stockscreener-App
3.91
1.04%
0.06
Schlusskurs vom Vortag:
$3.85
Offen:
$3.86
24-Stunden-Volumen:
36,021
Relative Volume:
0.24
Marktkapitalisierung:
$157.34M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$63.21M
KGV:
2.6325
EPS:
1.4853
Netto-Cashflow:
$-9.71M
1W Leistung:
+1.83%
1M Leistung:
+11.46%
6M Leistung:
+69.87%
1J Leistung:
+69.87%
1-Tages-Spanne:
$3.86
$3.94
1-Wochen-Bereich:
$3.66
$3.96
52-Wochen-Spanne:
$1.975
$3.96
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.89 | 155.72M | 2.00M | 63.21M | -9.71M | 1.4853 |
VRTX
Vertex Pharmaceuticals Inc
|
436.81 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.68 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
794.59 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
311.23 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.06 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors - Yahoo Finance
Evolus and Oramed Pharmaceuticals Compared - National Today
Setup Watch: Is Oramed Pharmaceuticals Inc stock technically oversold2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Sell Signal: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Overview Summary & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Fund Flows: Can Oramed Pharmaceuticals Inc keep up with sector leadersMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Technical Analysis: Will Oramed Pharmaceuticals Inc face regulatory challenges2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Lifeward scoops US$20M after completing Oratech Pharma takeover - Mugglehead Investment Magazine
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ORMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Oramed Pharmaceuticals stock: Oral insulin pioneer or high-risk bet? - AD HOC NEWS
ORMP Should I Buy - Intellectia AI
ORMP Stock Price, Quote & Chart | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
Oramed Completes Oratech Sale and Strategic Lifeward Financing - The Globe and Mail
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oramed (ORMP) completes Oratech sale and buys $9M Lifeward notes - Stock Titan
Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax - Stock Titan
Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding - Stock Titan
FOMO Trade: Is Oramed Pharmaceuticals Inc stock good for income investorsMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Oramed Pharmaceuticals Hits New 52-Week High of $3.76, Up 75% Yearly - Markets Mojo
Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38 - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Oramed Pharmaceuticals: Oral Insulin Technology, Strategic Investments, and 2026 Business Overview - Minichart
Oramed: Q4 Earnings Snapshot - Barchart.com
Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS - TradingView — Track All Markets
Oramed (NASDAQ: ORMP) pivots with Lifeward deal and Alpha Tau stake - Stock Titan
Lifeward closes Oramed partnership, secures $10 million funding By Investing.com - Investing.com Australia
Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024. - marketscreener.com
Lifeward Closes Oramed Partnership, Acquires Oratech Pharma - Moomoo
Lifeward closes Oramed partnership, secures $10 million funding - Investing.com
Lifeward Successfully Closes on Strategic Partnership with Oramed - manilatimes.net
Lifeward adds biotech drug-delivery tech and taps up to $47M - Stock Titan
Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc.. - marketscreener.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Oramed Pharmaceuticals Inc expected to post breakeven results a shareEarnings Preview - TradingView
Surprises Report: Does Oramed Pharmaceuticals Inc stock benefit from AI growth2026 Macro Impact & Pattern Based Trade Signal System - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday - MarketBeat
Market Overview: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
[Form 4] ORAMED PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Oramed (NASDAQ: ORMP) CEO receives 167,005 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) COO receives 95,889 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) CFO receives 95,889 RSU equity award - Stock Titan
Oramed deal reshapes Lifeward (NASDAQ: LFWD) with new tech and funding - Stock Titan
Oral insulin and robotic exoskeletons: Lifeward’s $47M pivot - Stock Titan
Retail Trends: How sensitive is Oramed Pharmaceuticals Inc to inflationWeekly Trade Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Is Oramed Pharmaceuticals Inc stock undervalued right nowEarnings Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Returns Recap: Is Oramed Pharmaceuticals Inc stock a smart retirement pickMarket Volume Report & High Yield Stock Recommendations - baoquankhu1.vn
Oramed (ORMP) CEO donates 100,000 shares to charity - Stock Titan
Lifeward shareholders approve Oramed partnership deal By Investing.com - Investing.com India
Lifeward shareholders approve Oramed partnership deal - Investing.com
Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability - Quiver Quantitative
Lifeward Receives Shareholder Approval to Close on - globenewswire.com
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oramed Pharmaceuticals Inc-Aktie (ORMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kidron Miriam | Chief Scientific Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
1,448,664 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
1.40%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):